The Business of Anti-Aging Science

Trends Biotechnol. 2017 Nov;35(11):1062-1073. doi: 10.1016/j.tibtech.2017.07.004. Epub 2017 Aug 1.


Age-related conditions are the leading causes of death and health-care costs. Reducing the rate of aging would have enormous medical and financial benefits. Myriad genes and pathways are known to regulate aging in model organisms, fostering a new crop of anti-aging companies. Approaches range from drug discovery efforts to big-data methods and direct-to-consumer (DTC) strategies. Challenges and pitfalls of commercialization include reliance on findings from short-lived model organisms, poor biological understanding of aging, and hurdles in performing clinical trials for aging. A large number of potential aging-associated interventions and targets exist, but given the long validation times only a small fraction can be explored for clinical applications. If even one company succeeds, however, the impact will be huge.

Keywords: Big Pharma; biogerontology; geroscience; longevity; pharmacology; translational research.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging*
  • Animals
  • Biomedical Research* / methods
  • Biomedical Research* / trends
  • Biotechnology* / methods
  • Biotechnology* / trends
  • Humans